← Leaderboards
Brian Garriock Firth
Thrombolex, Inc.
$2,964,550
Attributed
$2,964,550
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1000K · FY2020–22$1M$750K$500K$250K$0
'20
'21
'22
Funding mix
By agency
NIH$2,964,550 · 1
By mechanism
R44$2,964,550 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Adverse Effects”
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Kristin Aillon · Midwest Research Institute$23,644,534
- Abraham Aizer Brody · New York University School Of Medicine$21,887,280
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$21,828,548
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
Research focus
Adverse EffectsAffectAlteplaseAmericanAreaBloodBlood CoagulationBlood FlowCaliberCardiovascular CollapseCathetersCoagulation ProcessCommercializationCompare EffectivenessData AnalysesDeep Vein ThrombosisDesignDevicesDoseDrug Delivery SystemsEffectivenessEffectiveness EvaluationEfficacy TrialAcute
Grant awards (3)
Novel Expandable Infusion Catheter for the Treatment of Acute Pulmonary Embolism$978,998
R44 · FY2022 · HL · contact PI
Novel Expandable Infusion Catheter for the Treatment of Acute Pulmonary Embolism$985,555
R44 · FY2021 · HL · contact PI
Novel Expandable Infusion Catheter for the Treatment of Acute Pulmonary Embolism$999,997
R44 · FY2020 · HL · contact PI